Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 55154-8188

5 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 55154-8188). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Chemical Structure Of Sevelamer Carbonate (Structure)

Figure 1: Chemical Structure Of Sevelamer Carbonate (Structure)
Chemical structure diagram of the active ingredient Sevelamer Carbonate, showing its polymeric network with primary amine groups, crosslinking groups, and bicarbonate ions as part of its extended polymer structure.*
FDA Label Image

Figure 2. Change In Serum Phosphorus (mg/dl) From Baseline To Week 2 By Subgroup (Figure 2)

Figure 2. Change In Serum Phosphorus (mg/dl) From Baseline To Week 2 By Subgroup (Figure 2)
A forest plot chart showing subgroup analyses comparing Sevelamer Carbonate versus placebo. It displays subgroups by screening body surface area, baseline serum phosphorus, age, and dialysis status. Each subgroup lists sample sizes, LS mean differences, and 95% confidence intervals, with a horizontal axis indicating favor towards Sevelamer Carbonate or placebo.*
FDA Label Image

Figure 3: Percentage Of Patients (y-axis) Attaining A Phosphorus Reduction From Baseline (mg/dl) At Least As Great As The Value Of The X-axis (Figure 3)

Figure 3: Percentage Of Patients (y-axis) Attaining A Phosphorus Reduction From Baseline (mg/dl) At Least As Great As The Value Of The X-axis (Figure 3)
A line graph comparing the percentage of patients with reductions in serum phosphorus levels for Sevelamer Hydrochloride versus an active control. The x-axis shows reduction in serum phosphorus (mg/dL) from -4 to 8, and the y-axis shows the percentage of patients with reduction ≥x from 0% to 100%. The graph illustrates changes in phosphorus reduction, including worsened increase and improved reduction from baseline.*
FDA Label Image

Figure 4: Mean Phosphorus Change From Baseline For Patients Who Completed 52 Weeks Of Treatment (Image 01)

Figure 4: Mean Phosphorus Change From Baseline For Patients Who Completed 52 Weeks Of Treatment (Image 01)
Line graph showing phosphorus change from baseline over 52 study weeks comparing Sevelamer Hydrochloride and Active-Control treatments. The y-axis represents phosphorus change values from -5 to 2, and the x-axis represents study weeks from 0 to 52. Both treatments show an initial phosphorus decrease with relatively stable levels thereafter.*
FDA Label Image

800mg Bag Label (1e7c0036 B057 E32a E063 6394a90a6caf 00)

800mg Bag Label (1e7c0036 B057 E32a E063 6394a90a6caf 00)
Sevelamer Carbonate Tablets 800 mg film-coated, oral dosage form, packaged in a unit dose of 10 tablets. The label includes active ingredient and inactive ingredients information, storage instructions, and warnings. Distributed by Cardinal Health and American Health Packaging, with NDC 55154-8188.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.